Ipilimumab联合放疗在转移性去势抵抗性前列腺癌的最终分析:长期生存者增多
CA184-043 III期试验纳入799例多西他赛后mCRPC患者,随机接受骨转移灶单次放疗后Ipilimumab或安慰剂。最终分析显示生存曲线7-8月交叉后持续分离,5年OS率7.9%对2.7%,3-5年OS率约高2-3倍。
要点
- 最终分析示Ipilimumab组3、4、5年OS率均高于安慰剂组。
- 分段风险模型示HR随时间变化:0-5月1.49,5月后0.66。
- 两组死亡主因均为疾病进展,长期未见新安全信号。
核心结论
- 在多西他赛后mCRPC患者中,放疗后联合Ipilimumab较安慰剂延长长期生存,3-5年OS率约高2-3倍。
研究设计与样本
- III期随机对照试验CA184-043,799例多西他赛后mCRPC患者随机接受骨转移灶单次放疗后Ipilimumab(n=399)或安慰剂(n=400),按意向治疗分析OS。
主要发现
- 中位额外随访约2.4年,721/799例患者死亡。
- 生存曲线在7-8月交叉后持续分离, favoring Ipilimumab组。
- 分段风险模型HR:0-5月1.49(95%CI 1.12-1.99),5-12月0.66(0.51-0.86),12月后0.66(0.52-0.84)。
- OS率Ipilimumab组 vs 安慰剂组:2年25.2% vs 16.6%,3年15.3% vs 7.9%,4年10.1% vs 3.3%,5年7.9% vs 2.7%。
- 两组最常见死因均为疾病进展;研究药物毒性为主要死因者Ipilimumab组7例(1.8%),安慰剂组1例(0.3%)。
临床怎么用
- 对于多西他赛后mCRPC患者,可考虑骨转移灶放疗后联合Ipilimumab以改善长期生存,但需注意早期(0-5月)风险升高。
局限性
- 原文未报告主要终点未达显著后的其他预设分析细节,且长期随访数据来自额外2.4年,需谨慎解读亚组结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The phase 3 trial CA184-043 evaluated radiotherapy to bone metastases followed by Ipilimumab or placebo in men with metastatic castrate-resistant prostate cancer (mCRPC) who had received docetaxel previously. In a prior analysis, the trial's primary endpoint (overall survival [OS]) was not improved significantly. OBJECTIVE: To report the final analysis of OS. DESIGN, SETTING, AND PARTICIPANTS: A total of 799 patients were randomized to receive a single dose of radiotherapy to one or more bone metastases followed by either Ipilimumab (n = 399) or placebo (n = 400). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: OS was analyzed in the intention-to-treat population. Prespecified and exploratory subset analyses based on Kaplan-Meier/Cox methodology were performed. RESULTS AND LIMITATIONS: During an additional follow-up of approximately 2.4 yr since the primary analysis, 721/799 patients have died. Survival analysis showed crossing of the curves at 7-8 mo, followed by persistent separation of the curves beyond that point, favoring the ipilimumab arm. Given the lack of proportional hazards, a piecewise hazard model showed that the hazard ratio (HR) changed over time: the HR was 1.49 (95% confidence interval 1.12, 1.99) for 0-5 mo, 0.66 (0.51, 0.86) for 5-12 mo, and 0.66 (0.52, 0.84) beyond 12 mo. OS rates were higher in the ipilimumab versus placebo arms at 2 yr (25.2% vs 16.6%), 3 yr (15.3% vs 7.9%), 4 yr (10.1% vs 3.3%), and 5 yr (7.9% vs. 2.7%). Disease progression was the most frequent cause of death in both arms. In seven patients (1.8%) in the ipilimumab arm and one (0.3%) in the placebo arm, the primary cause of death was reported as study drug toxicity. No long-term safety signals were identified. CONCLUSIONS: In this preplanned long-term analysis, OS favored ipilimumab plus radiotherapy versus placebo plus radiotherapy for patients with postdocetaxel mCRPC. OS rates at 3, 4, and 5 yr were approximately two to three times higher in the ipilimumab arm. PATIENT SUMMARY: After longer follow-up, survival favored the group of men who received ipilimumab, with overall survival rates being two to three times higher at 3 yr and beyond.
引用
- Fizazi K, Drake CG, Beer TM, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol. 2020. PMID: 32811715. doi:10.1016/j.eururo.2020.07.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。